Eli Lilly presented early clinical data for brenipatide, its GIP/GLP-1 receptor agonist candidate, supporting once-weekly dosing selection for substance use, psychiatric, and immunologic disorders. The company also laid out Phase III trial designs for major depressive disorder and alcohol use disorder. In the Phase I J2S-MC-GZMD trial, Lilly reported pharmacokinetics consistent with a mean half-life ranging roughly from nine to 12.5 days across studied dose levels, including the higher 4.5 mg cohort. The dosing durability was described as extending beyond the weekly interval while the program advances. The asset leverages Lilly’s experience with tirzepatide while shifting receptor targeting to the central nervous system and inflammatory pathways associated with reward and addiction biology.